Thalassemia Market Summary
The Thalassemia Market Size is anticipated to grow with a significant CAGR during the study period (2020–2034). Thalassemia is the most common form of inherited anemia worldwide, with the World Health Organization reporting that about 60,000 infants are born with major thalassemia every year.
Alpha- and beta-thalassemia treatment depends on disease severity and includes regular blood transfusions, iron chelation therapy to manage iron overload, and curative options like stem cell transplantation or gene therapy; milder cases may not require treatment, while newer targeted therapies are showing promising potential.
Currently, there are no approved therapies for alpha thalassemia; however, certain therapies are approved for beta thalassemia, including CASGEVY (Vertex Pharmaceuticals), ZYNTEGLO (Bluebird Bio), REBLOZYL (Bristol-Myers Squibb), and others. The pipeline for thalassemia, while not very robust, features key players such as Agios Pharmaceuticals (PYRUKYND), Novo Nordisk (etavopivat), and Regeneron Pharmaceuticals (REGN7999) conducting trials for the treatment of patients with thalassemia.
In January 2025, Agios Pharmaceuticals announced that the US FDA accepted for review the supplemental New Drug Application (sNDA) for mitapivat for the treatment of adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, with a PDUFA goal date of September 7, 2025.
Awareness around thalassemia is steadily increasing, driven by advancements in diagnostics, improved management strategies, and the emergence of curative approaches such as stem cell and gene therapy. As a result, the thalassemia treatment market is expected to witness significant growth in the coming years, supported by rising demand for effective therapies and broader healthcare access.
Explore DelveInsight’s Full Coverage on the Thalassemia Market
Thalassemia Overview
Thalassemia is a genetic blood disorder in which the body produces insufficient hemoglobin, the protein in red blood cells responsible for carrying oxygen throughout the body. This results in fewer and less effective red blood cells, leading to anemia – a condition marked by fatigue, weakness, and other symptoms due to reduced oxygen delivery to tissues. Thalassemia is inherited from one or both parents and varies in severity, from mild forms with little to no symptoms to severe forms requiring regular blood transfusions.
It is more common in people of Mediterranean, Middle Eastern, South Asian, and African ancestry. The condition can affect either the alpha or beta part of hemoglobin, giving rise to alpha thalassemia or beta thalassemia, respectively.
Thalassemia Diagnosis and Treatment Algorithm
Thalassemia is typically diagnosed through a combination of medical history, family history, and specialized blood and genetic tests. If symptoms are mild or absent, it may be detected incidentally during a routine blood test; in more severe cases, signs often appear before the age of two. To confirm a diagnosis, healthcare providers may conduct a complete blood count (CBC) to assess hemoglobin levels and red blood cell characteristics, special hemoglobin tests to identify abnormal hemoglobin types, and genetic testing to determine the specific form of thalassemia.
Treatment for thalassemia depends on its type and severity. Carriers or individuals with mild forms like alpha or beta thalassemia trait may not need treatment. More serious types – such as hemoglobin H disease, beta thalassemia intermedia, or major – often require regular or occasional blood transfusions to manage anemia. Frequent transfusions can cause iron overload, which is managed through iron chelation therapy using medications like deferasirox, deferiprone, or deferoxamine. In severe cases, a blood or bone marrow transplant may offer a cure, though donor matches are limited. Additional treatments may include medications like luspatercept or hydroxyurea to reduce transfusion needs, and splenectomy in certain cases to improve symptoms.
Thalassemia Market Players
Key companies operating in the Thalassemia market research landscape include:
- Vertex Pharmaceuticals
- Bluebird Bio
- Bristol-Myers Squibb
- Agios Pharmaceuticals
- Novo Nordisk
- Regeneron Pharmaceuticals
- And Others.
Thalassemia Epidemiology
The epidemiology section of the Thalassemia market insight report provides historical and projected patient population data across the seven major markets (7MM), supported by key opinion leader perspectives that contextualize observed and anticipated trends. Relevant tables and graphs offer a clear view of prevalence patterns, with disclosed assumptions ensuring transparency in data interpretation. This section provides a robust understanding of disease burden across regions.
Key Findings:
- About 300 million people around the world have the “thalassemia trait,” which puts them at risk of having children with some form of thalassemia
- More than 1 million people have non-transfusion-dependent thalassemia, while more than 100,000 people have transfusion-dependent thalassemia; in the US, there are at least 1,200 people with transfusion-dependent thalassemia
- In 2021, there were 1,310,407 cases of thalassemia globally
- Worldwide, at least 300,000 children are born each year affected with a severe form of hemoglobinopathy; furthermore, at least 20% of the global population carries at least a single gene deletion for alpha thalassemia
- Globally, the Age-standardized Prevalence Rate (ASPR) for thalassemia in 2021 was 18.28 per 100,000 persons
- The number of β-thalassemia prevalent cases in the US was previously estimated at 2,600
- In Italy in 2021, more than 400,000 people were recorded with rare disease, with approximately 90 million carriers of beta-thalassemia worldwide
- The epidemiology of thalassemia is expected to evolve during the forecast period (2025–2034)
Thalassemia Market Outlook
The Thalassemia market trends point to continued expansion through the forecast period (2025–2034), driven by a rising prevalent population, technological advancements, and a growing pipeline of novel therapeutics. The thalassemia market is anchored by regular blood transfusions and iron chelation therapies to manage anemia and prevent iron overload. Curative options like stem cell transplants are limited by donor availability.
There are no marketed drugs for alpha thalassemia; however, there are marketed drugs for beta thalassemia, including CASGEVY, ZYNTEGLO, and REBLOZYL. Emerging therapies such as PYRUKYND aim to reduce transfusion dependence and are expected to reshape the long-term treatment outlook.
Key Thalassemia companies, such as Agios Pharmaceuticals, Novo Nordisk, and others, are evaluating their lead candidates in different stages of clinical development, aiming to investigate their products for the treatment of thalassemia.
Marketed Thalassemia Drugs
- CASGEVY (exagamglogene autotemcel) – Vertex Pharmaceuticals
CASGEVY is the first FDA-approved therapy utilizing CRISPR/Cas9, a type of genome editing technology. It is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy for eligible patients with sickle-cell disease or transfusion-dependent beta thalassemia, in which a patient’s own hematopoietic stem and progenitor cells are edited at the erythroid-specific enhancer region of the BCL11A gene through a precise double-strand break. This edit results in the production of high levels of fetal hemoglobin (HbF) in red blood cells. CASGEVY has been shown to reduce or eliminate transfusion requirements for patients with transfusion-dependent beta thalassemia.
- In January 2024, the US FDA approved CASGEVY for the treatment of transfusion-dependent beta thalassemia in patients 12 years and older
- REBLOZYL (luspatercept) – Bristol-Myers Squibb
REBLOZYL is a first-in-class therapeutic option that promotes late-stage red blood cell maturation in animal models. REBLOZYL is being developed and commercialized through a global collaboration with Merck as of November 2021. It is indicated in the US for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions.
- In November 2019, the US FDA approved REBLOZYL for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions
Download the Thalassemia market report for in-depth insights on pipeline and forecast
Emerging Thalassemia Drugs
The Thalassemia market size is expected to evolve significantly, supported by an active pipeline of emerging therapies addressing substantial unmet need. Key emerging candidates include PYRUKYND (mitapivat), etavopivat, and REGN7999, among others, with active development programs targeting novel mechanisms, improved tolerability, and durable disease control.
- PYRUKYND (mitapivat) – Agios Pharmaceuticals
PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency in the US, and for the treatment of PK deficiency in adult patients in the European Union. The US FDA has accepted for review the sNDA for mitapivat for the treatment of adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia.
- In June 2025, Agios Pharmaceuticals presented new data on the company’s PK activators, mitapivat and tebapivat, featured in oral and poster presentations during the 30th European Hematology Association (EHA) Congress 2025
- Etavopivat (FT-4202) – Novo Nordisk
Etavopivat is a small-molecule activator of the enzyme Pyruvate Kinase R (PKR). In its active state, PKR pushes red blood cells to produce energy, and 2,3-DPG levels drop. By reducing the levels of 2,3-DPG and increasing the production of energy, etavopivat should allow stronger binding of oxygen to the faulty hemoglobin protein, thereby prolonging red blood cell survival, easing anemia, and reducing VOC frequency. It is currently being evaluated in Phase III for thalassemia in clinical trials.
- REGN7999 – Regeneron Pharmaceuticals
REGN7999 targets TMPRSS6 and is currently in Phase II clinical development for iron overload in beta-thalassemia.
Thalassemia Drugs Uptake
This section examines the sales uptake of potential thalassemia drugs launched or anticipated to launch between 2025 and 2034, estimating market penetration across countries and evaluating their impact within and across therapeutic classes and segments. It also addresses the financial and regulatory factors contributing to the probability of success of drugs in the thalassemia market.
Emerging therapies are analyzed on the basis of safety and efficacy in randomized clinical trials, order of market entry, broader market dynamics, and the degree to which they address unmet need within the thalassemia treatment landscape.
Conclusion
The Thalassemia market is poised for meaningful growth through 2034, supported by an increasing disease burden, heightened awareness, and continued advancements in therapeutic innovation. While blood transfusions and iron chelation therapy remain the cornerstone of disease management, persistent unmet needs – particularly in curative access, alpha thalassemia treatment options, and reducing transfusion dependence – are driving the development of next-generation agents with novel mechanisms. Promising pipeline candidates such as PYRUKYND (mitapivat), etavopivat, and REGN7999 have the potential to reshape the treatment landscape and enhance patient outcomes. As research progresses and access to innovative therapies expands, the Thalassemia market is expected to witness significant transformation, creating new opportunities for stakeholders while addressing the long-term challenges associated with this debilitating condition.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail: abhishek@delveinsight.com
